Published in J Exp Med on April 20, 1998
BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med (1999) 6.27
The many roles of FAS receptor signaling in the immune system. Immunity (2009) 4.67
Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis (2010) 3.69
APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med (1998) 3.17
Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med (2002) 3.02
Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles (2015) 3.02
Disorders of lysosome-related organelle biogenesis: clinical and molecular genetics. Annu Rev Genomics Hum Genet (2008) 2.83
Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med (1999) 2.76
Caspase activation is required for T cell proliferation. J Exp Med (1999) 2.74
Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature (2009) 2.54
Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol (2003) 2.50
Life and death by death receptors. FASEB J (2009) 2.39
FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol (2001) 2.39
CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev (2002) 2.35
Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med (2007) 2.32
Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest (1999) 2.32
Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med (1999) 2.13
CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J (2004) 2.12
N-terminal fragment of c-FLIP(L) processed by caspase 8 specifically interacts with TRAF2 and induces activation of the NF-kappaB signaling pathway. Mol Cell Biol (2004) 2.11
Fas ligand, Bcl-2, granulocyte colony-stimulating factor, and p38 mitogen-activated protein kinase: Regulators of distinct cell death and survival pathways in granulocytes. J Exp Med (2000) 2.07
Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med (2005) 2.03
Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x(L). Proc Natl Acad Sci U S A (1999) 1.99
Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med (1999) 1.88
CD95, BIM and T cell homeostasis. Nat Rev Immunol (2009) 1.73
Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep (2001) 1.66
Fas death receptor signalling: roles of Bid and XIAP. Cell Death Differ (2011) 1.63
Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J (1999) 1.59
Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp Med (2000) 1.56
Phagocytosis of necrotic cells by macrophages is phosphatidylserine dependent and does not induce inflammatory cytokine production. Mol Biol Cell (2003) 1.47
Role of membrane sphingomyelin and ceramide in platform formation for Fas-mediated apoptosis. J Exp Med (2005) 1.46
Two CD95 tumor classes with different sensitivities to antitumor drugs. Proc Natl Acad Sci U S A (2003) 1.41
Hepatic stellate cells express the low affinity nerve growth factor receptor p75 and undergo apoptosis in response to nerve growth factor stimulation. Am J Pathol (2000) 1.39
Requirement of biphasic calcium release from the endoplasmic reticulum for Fas-mediated apoptosis. J Cell Biol (2006) 1.36
Immune evasion by murine melanoma mediated through CC chemokine receptor-10. J Exp Med (2003) 1.34
Membrane tumor necrosis factor (TNF) induces p100 processing via TNF receptor-2 (TNFR2). J Biol Chem (2009) 1.33
Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. Neoplasia (2002) 1.33
Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J Exp Med (2012) 1.32
Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. J Immunol (1999) 1.26
Monocytes treated with human immunodeficiency virus Tat kill uninfected CD4(+) cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism. J Virol (2003) 1.25
Death receptors as targets in cancer. Br J Pharmacol (2013) 1.24
TNF superfamily: a growing saga of kidney injury modulators. Mediators Inflamm (2010) 1.20
Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. J Virol (2006) 1.18
Ionizing radiation and chemotherapeutic drugs induce apoptosis in lymphocytes in the absence of Fas or FADD/MORT1 signaling. Implications for cancer therapy. J Exp Med (2000) 1.16
Transforming growth factor beta1 inhibits Fas ligand expression and subsequent activation-induced cell death in T cells via downregulation of c-Myc. J Exp Med (1999) 1.14
Apoptosis in alpha interferon (IFN-alpha) intratumoral chemotherapy for cystic craniopharyngiomas. Childs Nerv Syst (2007) 1.14
Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway. J Biol Chem (2010) 1.13
The extracellular domains of FasL and Fas are sufficient for the formation of supramolecular FasL-Fas clusters of high stability. J Cell Biol (2005) 1.10
The naturally processed CD95L elicits a c-yes/calcium/PI3K-driven cell migration pathway. PLoS Biol (2011) 1.08
Immune escape mechanisms of intraocular tumors. Prog Retin Eye Res (2009) 1.07
Death receptors as targets for anti-cancer therapy. J Cell Mol Med (2008) 1.07
Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells. Front Oncol (2015) 1.05
Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy. ISRN Oncol (2013) 1.04
Membrane-bound Fas ligand requires RIP1 for efficient activation of caspase-8 within the death-inducing signaling complex. J Immunol (2009) 1.01
Adjuvantive effects of anti-4-1BB agonist Ab and 4-1BBL DNA for a HIV-1 Gag DNA vaccine: different effects on cellular and humoral immunity. Vaccine (2009) 0.99
Matrix metalloproteinases and soluble Fas/FasL system as novel regulators of apoptosis in children and young adults on chronic dialysis. Apoptosis (2011) 0.98
Nanoscale arrangement of apoptotic ligands reveals a demand for a minimal lateral distance for efficient death receptor activation. Nano Lett (2009) 0.98
The Pla protease of Yersinia pestis degrades fas ligand to manipulate host cell death and inflammation. Cell Host Microbe (2014) 0.98
Functional analysis of Ectodysplasin-A mutations causing selective tooth agenesis. Eur J Hum Genet (2010) 0.98
Regulating TRAIL receptor-induced cell death at the membrane : a deadly discussion. Recent Pat Anticancer Drug Discov (2011) 0.97
The biological activity of FasL in human and mouse lungs is determined by the structure of its stalk region. J Clin Invest (2011) 0.96
Calmodulin mediates Fas-induced FADD-independent survival signaling in pancreatic cancer cells via activation of Src-extracellular signal-regulated kinase (ERK). J Biol Chem (2011) 0.96
Hodgkin disease and the role of the immune system. Pediatr Hematol Oncol (2011) 0.95
Mechanism of Fas signaling regulation by human herpesvirus 8 K1 oncoprotein. J Natl Cancer Inst (2009) 0.95
Transcription-controlled gene therapy against tumor angiogenesis. J Clin Invest (2004) 0.94
Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets. Future Oncol (2012) 0.93
Biological activity of ectodysplasin A is conditioned by its collagen and heparan sulfate proteoglycan-binding domains. J Biol Chem (2009) 0.92
Exosomes: novel organelles implicated in immunomodulation and apoptosis. Yale J Biol Med (2002) 0.92
Posttranslational regulation of Fas ligand function. Cell Commun Signal (2008) 0.90
Membrane trafficking of death receptors: implications on signalling. Int J Mol Sci (2013) 0.89
Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase. Am J Pathol (1998) 0.89
Onto better TRAILs for cancer treatment. Cell Death Differ (2016) 0.88
The role of CD95 and CD95 ligand in cancer. Cell Death Differ (2015) 0.88
Molecular and therapeutic characterization of anti-ectodysplasin A receptor (EDAR) agonist monoclonal antibodies. J Biol Chem (2011) 0.88
Cytotoxic T lymphocytes derived from patients with chronic hepatitis C virus infection kill bystander cells via Fas-FasL interaction. J Virol (2004) 0.88
Soluble Fas ligand inhibits angiogenesis in rheumatoid arthritis. Arthritis Res Ther (2007) 0.86
The strength of the Fas ligand signal determines whether hepatocytes act as type 1 or type 2 cells in murine livers. Hepatology (2009) 0.86
The 19 kDa Mycobacterium tuberculosis lipoprotein (LpqH) induces macrophage apoptosis through extrinsic and intrinsic pathways: a role for the mitochondrial apoptosis-inducing factor. Clin Dev Immunol (2012) 0.86
Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity. Cell Death Dis (2012) 0.85
Mitomycin C induces bystander killing in homogeneous and heterogeneous hepatoma cellular models. Mol Cancer (2009) 0.85
Overexpression of membrane-bound fas ligand (CD95L) exacerbates autoimmune disease and renal pathology in pristane-induced lupus. J Immunol (2013) 0.85
Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males. Arthritis Res Ther (2008) 0.84
Up-regulation of Fas (CD95) expression in tumour cells in vivo. Immunology (2007) 0.84
FAS-dependent cell death in α-synuclein transgenic oligodendrocyte models of multiple system atrophy. PLoS One (2013) 0.84
Principles of antibody-mediated TNF receptor activation. Cell Death Differ (2015) 0.84
A biochemical mechanism for resistance of intervertebral discs to metastatic cancer: Fas ligand produced by disc cells induces apoptotic cell death of cancer cells. Eur Spine J (2007) 0.83
Fas ligand exerts its pro-inflammatory effects via neutrophil recruitment but not activation. Immunology (2007) 0.83
Cumulus cells accelerate oocyte aging by releasing soluble Fas ligand in mice. Sci Rep (2015) 0.83
Exploring codon optimization and response surface methodology to express biologically active transmembrane RANKL in E. coli. PLoS One (2014) 0.83
Exosomes derived from mature dendritic cells increase endothelial inflammation and atherosclerosis via membrane TNF-α mediated NF-κB pathway. J Cell Mol Med (2016) 0.82
Crystal structure of human TWEAK in complex with the Fab fragment of a neutralizing antibody reveals insights into receptor binding. PLoS One (2013) 0.82
Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL. Br J Cancer (2008) 0.82
Sheeppox virus SPPV14 encodes a Bcl-2-like cell death inhibitor that counters a distinct set of mammalian proapoptotic proteins. J Virol (2012) 0.82
Signaling active CD95 receptor molecules trigger co-translocation of inactive CD95 molecules into lipid rafts. J Biol Chem (2012) 0.82
Design of CD40 agonists and their use in growing B cells for cancer immunotherapy. Int Rev Immunol (2012) 0.81
Oxidative stress increases Fas ligand expression in endothelial cells. J Inflamm (Lond) (2006) 0.81
Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3. BMC Cancer (2014) 0.81
Bench-to-bedside review: Ventilation-induced renal injury through systemic mediator release--just theory or a causal relationship? Crit Care (2011) 0.81
Fas and Fas ligand expression in cystic fibrosis airway epithelium. Thorax (1999) 0.81
Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes. J Biol Chem (1987) 34.69
Phase separation of integral membrane proteins in Triton X-114 solution. J Biol Chem (1981) 26.33
Apoptosis by death factor. Cell (1997) 14.42
The Fas death factor. Science (1995) 13.81
FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex. Cell (1996) 12.07
Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity (1995) 10.59
A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature (1997) 10.14
Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell (1996) 9.93
FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell (1995) 9.81
Lethal effect of the anti-Fas antibody in mice. Nature (1993) 9.20
Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) Nature (1995) 8.23
Fas ligand-induced apoptosis as a mechanism of immune privilege. Science (1995) 8.23
Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science (1989) 7.76
Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J (1995) 7.60
Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science (1994) 7.34
Caspases: killer proteases. Trends Biochem Sci (1997) 7.07
Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science (1997) 6.82
Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature (1997) 6.23
An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science (1997) 6.10
A role for CD95 ligand in preventing graft rejection. Nature (1995) 6.07
Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science (1996) 6.02
Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature (1994) 5.58
A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem (1995) 5.34
Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion? Nat Med (1996) 5.09
The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell (1995) 5.08
Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature (1994) 4.78
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J (1997) 4.28
Downregulation of Fas ligand by shedding. Nat Med (1998) 3.83
TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem (1997) 3.81
Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci U S A (1991) 3.76
Metalloproteinase-mediated release of human Fas ligand. J Exp Med (1995) 3.53
Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med (1995) 3.20
Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature (1994) 3.15
The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity (1997) 3.11
Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J (1995) 2.87
Mature T cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide. Proc Natl Acad Sci U S A (1993) 2.79
Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature (1994) 2.53
Fas ligand in human serum. Nat Med (1996) 2.53
Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med (1997) 2.46
A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol (1997) 2.31
Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol (1996) 2.14
Characterization of two receptors for TRAIL. FEBS Lett (1997) 1.82
Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med (1996) 1.80
Characterization of Fas (Apo-1, CD95)-Fas ligand interaction. J Biol Chem (1997) 1.58
Identification and characterization of a pro-tumor necrosis factor-alpha-processing enzyme from the ADAM family of zinc metalloproteases. J Biol Chem (1997) 1.52
Tumor necrosis factor-alpha as a proliferative signal for an IL-2-dependent T cell line: strict species specificity of action. J Immunol (1989) 1.39
Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr Biol (1996) 1.33
Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur J Immunol (1995) 1.30
Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol (1995) 1.26
Regulation of human B cell function by recombinant CD40 ligand and other TNF-related ligands. J Immunol (1995) 1.19
Characterization of the non-functional Fas ligand of gld mice. Int Immunol (1995) 1.06
Dimeric, trimeric and tetrameric complexes of immunoglobulin G fix complement. Biochem J (1980) 1.02
The relevance of apoptosis to AIDS pathogenesis. Trends Cell Biol (1995) 0.91
Expression of biologically active mouse and human CD95/APO-1/Fas ligand in the baculovirus system. J Immunol Methods (1996) 0.84
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ (2008) 10.45
Inhibition of death receptor signals by cellular FLIP. Nature (1997) 9.58
Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ (2007) 8.85
Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol (2000) 8.49
Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med (1999) 7.41
BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med (1999) 6.27
Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature (1997) 6.23
Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science (1996) 6.02
Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature (1994) 5.70
Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature (1994) 5.58
BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science (2001) 4.79
NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol (2001) 4.55
Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ (2006) 4.16
Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. J Exp Med (1991) 4.15
Astrocytes present myelin basic protein to encephalitogenic T-cell lines. Nature (1984) 3.71
Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ (2009) 3.44
BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med (2000) 3.43
Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science (1996) 3.35
Production of prostaglandin E and an interleukin-1 like factor by cultured astrocytes and C6 glioma cells. J Immunol (1982) 3.24
APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med (1998) 3.17
The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr Biol (2000) 3.12
MyD88, an adapter protein involved in interleukin-1 signaling. J Biol Chem (1998) 3.09
Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity (1998) 3.03
Bcl-2 decreases the free Ca2+ concentration within the endoplasmic reticulum. Proc Natl Acad Sci U S A (2000) 2.87
Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science (1998) 2.84
TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol (2000) 2.80
Caspase activation is required for T cell proliferation. J Exp Med (1999) 2.74
BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J Exp Med (2000) 2.69
Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor. Nat Cell Biol (2000) 2.66
Isolation of a lytic, pore-forming protein (perforin) from cytolytic T-lymphocytes. J Biol Chem (1985) 2.62
TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity (1997) 2.60
A family of serine esterases in lytic granules of cytolytic T lymphocytes. Cell (1987) 2.58
Identification of a novel neuroligin in humans which binds to PSD-95 and has a widespread expression. Biochem J (2001) 2.55
Characterization of the endogenous deoxyribonuclease involved in nuclear DNA degradation during apoptosis (programmed cell death). EMBO J (1993) 2.50
The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing. Cell Death Differ (2007) 2.49
IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur J Immunol (1998) 2.44
A kinetic study of immune mediators in the lungs of mice infected with influenza A virus. J Immunol (1992) 2.43
The pyrin domain: a possible member of the death domain-fold family implicated in apoptosis and inflammation. Curr Biol (2001) 2.43
Antigen presentation and tumor cytotoxicity by interferon-gamma-treated microglial cells. Eur J Immunol (1987) 2.41
Clusterin: the intriguing guises of a widely expressed glycoprotein. Trends Biochem Sci (1992) 2.40
Formation of transmembrane tubules by spontaneous polymerization of the hydrophilic complement protein C9. Nature (1982) 2.35
Production and detection of cold antihydrogen atoms. Nature (2002) 2.31
Interleukin 1 activity in the synovial fluid of patients with rheumatoid arthritis. Rheumatol Int (1982) 2.24
Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family. EMBO J (1987) 2.23
The protein bcl-2 alpha does not require membrane attachment, but two conserved domains to suppress apoptosis. J Cell Biol (1994) 2.20
On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases. Eur J Immunol (1989) 2.20
The sequence and topology of human complement component C9. EMBO J (1985) 2.18
Low pH activates the vacuolating toxin of Helicobacter pylori, which becomes acid and pepsin resistant. J Biol Chem (1995) 2.17
Signals from within: the DNA-damage-induced NF-kappaB response. Cell Death Differ (2006) 2.16
Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol (1996) 2.14
The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med (1995) 2.08
Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Differ (2001) 2.08
Fas ligand, Bcl-2, granulocyte colony-stimulating factor, and p38 mitogen-activated protein kinase: Regulators of distinct cell death and survival pathways in granulocytes. J Exp Med (2000) 2.07
Regulation of lymphocyte proliferation and death by FLIP. Nat Rev Immunol (2001) 2.04
Tumor necrosis factor alpha in cerebrospinal fluid during bacterial, but not viral, meningitis. Evaluation in murine model infections and in patients. J Exp Med (1988) 2.02
The CARD domain: a new apoptotic signalling motif. Trends Biochem Sci (1997) 2.02
Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A (2000) 2.00
Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x(L). Proc Natl Acad Sci U S A (1999) 1.99
Identification of CARDIAK, a RIP-like kinase that associates with caspase-1. Curr Biol (1998) 1.97
A model of homelessness among male veterans of the Vietnam War generation. Am J Psychiatry (1994) 1.97
Polymerization of the ninth component of complement (C9): formation of poly(C9) with a tubular ultrastructure resembling the membrane attack complex of complement. Proc Natl Acad Sci U S A (1982) 1.96
Glucose induces beta-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes (2001) 1.95
Old galaxies in the young Universe. Nature (2004) 1.90
Astrocytes as antigen-presenting cells. I. Induction of Ia antigen expression on astrocytes by T cells via immune interferon and its effect on antigen presentation. J Immunol (1985) 1.88
Ceramide enables fas to cap and kill. J Biol Chem (2001) 1.88
Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated glycoprotein 2, a constituent of rat testis fluid. Proc Natl Acad Sci U S A (1989) 1.85
A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med (2000) 1.83
Characterization of two receptors for TRAIL. FEBS Lett (1997) 1.82
Granzyme A is an interleukin 1 beta-converting enzyme. J Exp Med (1995) 1.81
Correlation between sites of limited proteolysis and segmental mobility in thermolysin. Biochemistry (1986) 1.80
Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med (1996) 1.80